SCHEMBL7708516

SCHEMBL7708516

COc1ccccc1N1CCN(CC(O)COc2ccc(O)c(C(C)(C)C)c2)CC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.70
TP53 P04637 3/20 0.69
KCNH2 Q12809 2/20 0.67
CACNA1G O43497 1/20 0.67
LMNA P02545 6/20 0.66
ALDH1A1 P00352 3/20 0.62
HSP90AB1 P08238 2/20 0.60
KDM4E B2RXH2 3/20 0.59
HPGD P15428 1/20 0.59
HSD17B10 Q99714 1/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
MAPK1 P28482 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
HIF1A Q16665 2/20 0.59
NR1I2 O75469 1/20 0.59
NR3C1 P04150 1/20 0.59
ADRB1 P08588 1/20 0.59
HTR1A P08908 1/20 0.59
ADRA2A P08913 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7711145 0.99 MAPT (0.69) MAPTTP53KCNH2CACNA1GLMNA
SCHEMBL7708515 0.89 MAPT (0.80) MAPTTP53KCNH2CACNA1GLMNA
Hydrochloric Acid SCHEMBL7705119 0.88 MAPT (0.79) MAPTTP53KCNH2CACNA1GLMNA
SCHEMBL9410198 0.87 MAPT (0.82) MAPTTP53KCNH2CACNA1GLMNA
Hydrochloric Acid SCHEMBL9410223 0.86 MAPT (0.81) MAPTTP53KCNH2CACNA1GLMNA
SCHEMBL7711545 0.86 MAPT (0.71) MAPTTP53KCNH2CACNA1GLMNA
SCHEMBL9005304 0.85 ABCB1 (0.53) MAPTHSP90AB1
SCHEMBL8435309 0.85 ABCB1 (0.53) MAPTHSP90AB1
SCHEMBL9410165 0.85 MAPT (0.81) MAPTTP53KCNH2CACNA1GLMNA
SCHEMBL29074454 0.85 MAPT (0.71) MAPTTP53KCNH2CACNA1GLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6358515-B2 ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITION; TREATMENT OF GLAUCOMA SENJU PHARMACEUTICAL CO., LTD. (JP) 2002-03-19 US claimed
US-20010008893-A1 HYDROQUINONE DERIVATIVES SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-07-19 US claimed
EP-0972766-A1 HYDROQUINONE DERIVATIVES Senju Pharmaceutical Co., Ltd. (JP) 2000-01-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010008893-A1 HYDROQUINONE DERIVATIVES REN, AGTR1, AGTR2 MAPT 4729/4885TP53 4157/4885KCNH2 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.